Subscribe or Manage Preferences

Gastrointestinal Cancers

The first-in-class cancer stem-cell inhibitor BBI608 demonstrated activity in advanced pancreatic cancer and colorectal cancer (CRC), according to results of 2 small studies reported at the 2016 Gastrointestinal Cancers Symposium.
Immune checkpoint inhibitors demonstrated varying degrees of activity in advanced gastric and esophageal cancers, according to preliminary clinical studies reported at the 2016 Gastrointestinal Cancers Symposium. The objective response rates ranged from 9% to 30% with 3 different PD-1 or PD-1 ligand 1 (PD-L1) inhibitors. The safety profiles were consistent with previous studies of checkpoint inhibitors.
The advantages of treatment at a high-volume center extended to adjuvant therapy in patients with resected pancreatic cancer, according to a study reported by Margaret T. Mandelson, PhD, MPH, Floyd and Dolores Jones Cancer Institute, Virginia Mason Medical Center, Seattle, WA, at the 2016 Gastrointestinal Cancers Symposium.

Results 1 - 3 of 3
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology